History of falls in Parkinson disease is associated with reduced cholinergic activity
Abstract
Objective: To investigate the relationships between history of falls and cholinergic vs dopaminergic denervation in patients with Parkinson disease (PD).
Background: There is a need to explore nondopaminergic mechanisms of gait control as the majority of motor impairments associated with falls in PD are resistant to dopaminergic treatment. Alterations in cholinergic neurotransmission in PD may be implicated because of evidence that gait control depends on cholinergic system–mediated higher-level cortical and subcortical processing, including pedunculopontine nucleus (PPN) function.
Methods: In this cross-sectional study, 44 patients with PD (Hoehn & Yahr stages I–III) without dementia and 15 control subjects underwent a clinical assessment and [11C]methyl-4-piperidinyl propionate (PMP) acetylcholinesterase (AChE) and [11C]dihydrotetrabenazine (DTBZ) vesicular monoamine transporter type 2 (VMAT2) brain PET imaging.
Results: Seventeen patients (38.6%) reported a history of falls and 27 patients had no falls. Analysis of covariance of the cortical AChE hydrolysis rates demonstrated reduced cortical AChE in the PD fallers group (−12.3%) followed by the PD nonfallers (−6.6%) compared to control subjects (F = 7.22, p = 0.0004). Thalamic AChE activity was lower only in the PD fallers group (−11.8%; F = 4.36, p = 0.008). There was no significant difference in nigrostriatal dopaminergic activity between PD fallers and nonfallers.
Conclusions: Unlike nigrostriatal dopaminergic denervation, cholinergic hypofunction is associated with fall status in Parkinson disease (PD). Thalamic AChE activity in part represents cholinergic output of the pedunculopontine nucleus (PPN), a key node for gait control. Our results are consistent with other data indicating that PPN degeneration is a major factor leading to impaired postural control and gait dysfunction in PD.
Get full access to this article
View all available purchase options and get full access to this article.
REFERENCES
1.
Bloem BR, Steijns JA, Smits-Engelsman BC. An update on falls. Curr Opin Neurol 2003;16:15–26.
2.
Bohnen NI, Cham R. Postural control, gait, and dopamine functions in parkinsonian movement disorders. Clin Geriatr Med 2006;22:797–812.
3.
Woollacott M, Shumway-Cook A. Attention and the control of posture and gait: a review of an emerging area of research. Gait Posture 2002;16:1–14.
4.
Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. J Neurol 2006;253:242–247.
5.
Mesulam MM, Geula C. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J Comp Neurol 1988;275:216–240.
6.
Heckers S, Geula C, Mesulam M. Cholinergic innervation of the human thalamus: dual origin and differential nuclear distribution. J Comp Neurol 1992;325:68–82.
7.
Lee MS, Rinne JO, Marsden CD. The pedunculopontine nucleus: its role in the genesis of movement disorders. Yonsei Med J 2000;41:167–184.
8.
Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinicopathologic study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–184.
9.
Hoehn M, Yahr M. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427–442.
10.
Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 1975;12:189–198.
11.
Fahn S, Elton R. Members of the UPDRS development committee: Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden C, Calne D, Goldstein M, eds. Recent Developments in Parkinson’s Disease. Florham Park, NJ: Macmillan Healthcare Information; 1987:153–164.
12.
Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson’s disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000;23:75–81.
13.
Thompson CJ, Kecani S, Boelen S. Evaluation of a neck-shield for use during neurological studies with a whole-body PET scanner. IEEE Trans Nucl Sci 2001;48:1512–1517.
14.
Jewett DM, Kilbourn MR, Lee LC. A simple synthesis of [11C]dihydrotetrabenazine (DTBZ). Nucl Med Biol 1997;24:197–199.
15.
Koeppe RA, Frey KA, Kume A, Albin R, Kilbourn MR, Kuhl DE. Equilibrium versus compartmental analysis for assessment of the vesicular monoamine transporter using (+)-alpha-[11C]dihydrotetrabenazine (DTBZ) and positron emission tomography. J Cereb Blood Flow Metab 1997;17:919–931.
16.
Snyder SE, Tluczek L, Jewett DM, Nguyen TB, Kuhl DE, Kilbourn MR. Synthesis of 1-[11C]methylpiperidin-4-yl propionate ([11C]PMP) for in vivo measurements of acetylcholinesterase activity. Nucl Med Biol 1998;25:751–754.
17.
Sitburana O, Ondo WG. Brain magnetic resonance imaging (MRI) in parkinsonian disorders. Parkinsonism Relat Disord 2009;15:165–174.
18.
Minoshima S, Koeppe RA, Fessler JA, et al. Integrated and automated data analysis method for neuronal activation studying using O15 water PET. Tokyo: Excerpta Medica; 1993:409–418.
19.
Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007;27:1533–1539.
20.
Nagatsuka S, Fukushi K, Shinotoh H, et al. Kinetic analysis of [(11)C]MP4A using a high-radioactivity brain region that represents an integrated input function for measurement of cerebral acetylcholinesterase activity without arterial blood sampling. J Cereb Blood Flow Metab 2001;21:1354–1366.
21.
Pahapill PA, Lozano AM. The pedunculopontine nucleus and Parkinson’s disease. Brain 2000;123:1767–1783.
22.
Shinotoh H, Namba H, Yamaguchi M, et al. Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson’s disease and progressive supranuclear palsy. Ann Neurol 1999;46:62–69.
23.
Litvan I, Blesa R, Clark K, et al. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy. Ann Neurol 1994;36:55–61.
24.
Nebes RD, Pollock BG, Halligan EM, Kirshner MA, Houck PR. Serum anticholinergic activity and motor performance in elderly persons. J Gerontol A Biol Sci Med Sci 2007;62:83–85.
25.
Bohnen NI, Kaufer DI, Hendrickson R, et al. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2005;76:315–319.
26.
Zesiewicz TA, Sullivan KL. Treatment of ataxia and imbalance with varenicline (Chantix): report of 2 patients with spinocerebellar ataxia (types 3 and 14). Clin Neuropharmacol 2008;31:363–365.
27.
Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003;60:1745–1748.
28.
Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson’s disease. Mov Disord 2006;21:1123–1130.
29.
Taylor JP, Rowan EN, Lett D, O’Brien JT, McKeith IG, Burn DJ. Poor attentional function predicts cognitive decline in patients with non-demented Parkinson’s disease independent of motor phenotype. J Neurol Neurosurg Psychiatry 2008;79:1318–1323.
30.
Yogev-Seligmann G, Hausdorff JM, Giladi N. The role of executive function and attention in gait. Mov Disord 2008;23:329–342.
31.
Namba H, Iyo M, Fukushi K, et al. Human cerebral acetylcholinesterase activity measured with positron emission tomography: procedure, normal values and effect of age. Eur J Nucl Med 1999;26:135–143.
Information & Authors
Information
Published In
Copyright
© 2009.
Publication History
Published online: November 16, 2009
Published in print: November 17, 2009
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Risk factors for falls in Parkinson's disease: a cross-sectional observational and Mendelian randomization study, Frontiers in Aging Neuroscience, 16, (2024).https://doi.org/10.3389/fnagi.2024.1420885
- Free-Water Imaging of the Nucleus Basalis of Meynert in Patients With Idiopathic REM Sleep Behavior Disorder and Parkinson Disease, Neurology, 102, 7, (2024)./doi/10.1212/WNL.0000000000209220
- Modulating the cholinergic system—Novel targets for deep brain stimulation in Parkinson's disease, Journal of Neurochemistry, (2024).https://doi.org/10.1111/jnc.16264
- Dynamic balance and gait impairments in Parkinson’s disease: novel cholinergic patterns, Brain Communications, 6, 5, (2024).https://doi.org/10.1093/braincomms/fcae286
- Cholinergic changes in Lewy body disease: implications for presentation, progression and subtypes, Brain, 147, 7, (2308-2324), (2024).https://doi.org/10.1093/brain/awae069
- The mesopontine tegmentum in reward and aversion: From cellular heterogeneity to behaviour, Neuroscience & Biobehavioral Reviews, 162, (105702), (2024).https://doi.org/10.1016/j.neubiorev.2024.105702
- No evidence for effects of low-intensity vestibular noise stimulation on mild-to-moderate gait impairments in patients with Parkinson’s disease, Journal of Neurology, 271, 8, (5489-5497), (2024).https://doi.org/10.1007/s00415-024-12504-z
- Low-intensity vestibular noise stimulation improves postural symptoms in progressive supranuclear palsy, Journal of Neurology, 271, 7, (4577-4586), (2024).https://doi.org/10.1007/s00415-024-12419-9
- Neuroimaging Biomarkers in Parkinson’s Disease, Neurophysiologic Biomarkers in Neuropsychiatric Disorders, (617-663), (2024).https://doi.org/10.1007/978-3-031-69491-2_21
- The Effect of taVNS at 25 Hz and 100 Hz on Parkinson's Disease Gait—A Randomized Motion Sensor Study , Movement Disorders, 39, 8, (1375-1385), (2024).https://doi.org/10.1002/mds.29826
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.